The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: A prospective observational study

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Pontororing, Gysje J ^a   Kenangalem, Enny ^a,e   Lolong, Dina B ^b   Waramori, Govert ^c   Sandjaja, ^b   Tjitra, Emiliana ^b   Price, Ric N ^a,f,g   Kelly, Paul M ^d   Anstey, Nicholas M ^a,f   Ralph, Anna P ^a,d  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^c Public Health and Malaria Control Department Papua   (Indonesia)

^d The Australian National University   (Australia)

^e District Health Authority   (Indonesia)

^f ROYAL DARWIN HOSPITAL   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; HEMOGLOBIN; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIOLOGY; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; EXERCISE TOLERANCE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HEALTH SURVEY; HIV TEST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; INDONESIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PLEURA EFFUSION; PRACTICE GUIDELINE; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS; WALKING; WORLD HEALTH ORGANIZATION; BIOLOGICAL MODEL; LUNG TUBERCULOSIS; PREVALENCE; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; INDONESIA; MALE; MODELS, BIOLOGICAL; PREVALENCE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, PULMONARY;

EID: 78651501793     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-362     Document Type: Article

References (54)

1. World Health Organisation Global tuberculosis control: Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411. 2009, WHO, Geneva, World Health Organisation.
2. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992, 146(6):1439-44.
3. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320(9):545-50. 10.1056/NEJM198903023200901, 2915665.
4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(9):1009-21. 10.1001/archinte.163.9.1009, 12742798.
5. Kang'ombe CT, Harries AD, Ito K, Clark T, Nyirenda TE, Aldis W, et al. Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tuberc Lung Dis 2004, 8(7):829-36.
6. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003, 37(1):101-12. 10.1086/375220, 12830415.
7. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010, 50(9):1288-99. 10.1086/651686, 20353364.
8. World Health Organisation WHO Three I's Meeting: Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and TB Infection Control (IC) for people living with HIV. Report of a Joint World Health Organization. HIV/AIDS and TB Department Meeting 2-4 Geneva, Switzerland. 2008, [updated June 2010], World Health Organisation., http://www.who.int/tb/publications/2009/who_3Is_meeting_report.pdf
9. World Health Organisation Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006, [August 2009], World Health Organisation., http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
10. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009, 13(1):6-16.
11. World Health Organisation, UNAIDS, UNICEF Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report. 2008, WHO, Geneva, [February 2010], World Health Organisation, UNAIDS, UNICEF., http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf
12. Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010s: is the glass half full?. Clin Infect Dis 2009, 49(4):574-83. 10.1086/600889, 19583517.
13. World Health Organisation Treatment of tuberculosis Guidelines Fourth edition WHO/HTM/TB/2009.420. 2010, WHO, Geneva, Switzerland, World Health Organisation., http://www.who.int/entity/tb/publications/tb_treatmentguidelines/en/index.html
14. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362(8):697-706. 10.1056/NEJMoa0905848, 20181971.
15. Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The "ART" of Linkage: Pre-Treatment Loss to Care after HIV Diagnosis at Two PEPFAR Sites in Durban, South Africa. PLoS One 2010, 5(3):e9538. 10.1371/journal.pone.0009538, 2832018, 20209059.
16. World Health Organisation A brief history of tuberculosis control in Indonesia WHO/HTM/TB/2009.424. 2009, Geneva, Switzerland, World Health Organisation., http://whqlibdoc.who.int/publications/2009/9789241598798_eng.pdf
17. Mahendradhata Y, Ahmad RA, Kusuma TA, Boelaert M, Van der Werf MJ, Kimerling ME, et al. Voluntary counselling and testing uptake and HIV prevalence among tuberculosis patients in Jogjakarta, Indonesia. Trans R Soc Trop Med Hyg 2008, 102(10):1003-10. 10.1016/j.trstmh.2008.04.042, 18571213.
18. World Health Organisation Indonesia: Summary country profile for HIV/AIDS treatment scale-up. 2005, [March 16, 2010], World Health Organisation., http://www.who.int/hiv/HIVCP_IDN.pdf
19. Statistics Indonesia and the Ministry of Health Risk Behaviour and HIV Prevalence in Tanah Papua 2006: Results of the IBBS 2006 in Tanah Papua. 2006, [February 2009], Statistics Indonesia and the Ministry of Health., http://siteresources.worldbank.org/INTINDONESIA/Resources/Publication/PapuaHIV_en.pdf
20. Riyarto S, Hidayat B, Johns B, Probandari A, Mahendradhata Y, Utarini A, et al. The financial burden of HIV care, including antiretroviral therapy, on patients in three sites in Indonesia. Health Policy Plan
21. National AIDS Commission Country report on the follow up to the declaration of commitment on HIV/AIDS. UNGASS: reporting period 2006-2007. Jakarta: National AIDS Commission. 2008, [March 16, 2010], National AIDS Commission., http://data.unaids.org/pub/Report/2008/indonesia_2008_country_progress_report_en.pdf
22. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J 2008, 7:148. 10.1186/1475-2875-7-148, 2518158, 18673572.
23. Ardian M, Meokbun E, Siburian L, Malonda E, Waramori G, Penttinen P, et al. A public-private partnership for TB control in Timika, Papua Province, Indonesia. Int J Tuberc Lung Dis 2007, 11(10):1101-7.
24. Kelly PM, Ardian M, Waramori G, Anstey NM, Syahrial H, Tjitra E, et al. A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia. Int J Tuberc Lung Dis 2006, 10(2):167-71.
25. Lumb R, Ardian M, Waramori G, Syahrial H, Tjitra E, Maguire GP, et al. An alternative method for sputum storage and transport for mycobacterium tuberculosis drug resistance surveys. Int J Tuberc Lung Dis 2006, 10(2):172-7.
26. Maguire GP, Anstey NM, Ardian M, Waramori G, Tjitra E, Kenangalem E, et al. Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis 2009, 13(12):1500-6.
27. Lyamuya EF, Aboud S, Urassa WK, Sufi J, Mbwana J, Ndugulile F, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009, 9:19. 10.1186/1471-2334-9-19, 2650699, 19226452.
28. Standard Diagnostics Inc SD HIV-1/2 3.0 point-of-care product information (packet insert). 2006, Standard Diagnostics Inc.
29. American Thoracic Society ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-7. American Thoracic Society.
30. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-7.
31. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, et al. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 2010, 65(10):863-9. 10.1136/thx.2010.136242, 20861290.
32. Lumb R, Bastian I. Laboratory diagnosis of tuberculosis by sputum microscopy: The Handbook. Pacific Island Countries. 2005, Adelaide, Australia: Institute of Medical and Veterinary Science.
33. Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology 2009, 14(7):1012-9. 10.1111/j.1440-1843.2009.01598.x, 19659516.
34. Telzak EE, Fazal BA, Pollard CL, Turett GS, Justman JE, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997, 25(3):666-70. 10.1086/513772, 9314458.
35. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-68. 10.1183/09031936.05.00035205, 16264058.
36. Wang L, Liu W, Wang L, Wang Y, Z W. HIV Prevalence Among Pulmonary Tuberculosis Patients in Guangxi, China. J Acquir Immune Defic Syndr 2010, 53(Suppl 1):S61-5.
37. Glynn JR, Carael M, Auvert B, Kahindo M, Chege J, Musonda R, et al. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. Aids 2001, 15(Suppl 4):S51-60. 10.1097/00002030-200108004-00006, 11686466.
38. Shetty PV, Granich RM, Patil AB, Sawant SK, Sahu S, Wares DF, et al. Cross-referral between voluntary HIV counselling and testing centres and TB services, Maharashtra, India, 2003-2004. Int J Tuberc Lung Dis 2008, 12(3 Suppl 1):26-31.
39. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008, 46(9):1374-81. 10.1086/586743, 2875100, 18419439.
40. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull World Health Organ 1992, 70(4):515-26. 2393393, 1394786.
41. Aderaye G, Bruchfeld J, Assefa G, Feleke D, Kallenius G, Baat M, et al. The relationship between disease pattern and disease burden by chest radiography, M. tuberculosis Load, and HIV status in patients with pulmonary tuberculosis in Addis Ababa. Infection 2004, 32(6):333-8. 10.1007/s15010-004-3089-x, 15597222.
42. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 2007, 45(12):4064-6. 10.1128/JCM.01780-07, 2168542, 17928422.
43. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360(9332):528-34. 10.1016/S0140-6736(02)09742-8, 12241657.
44. Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10(6):663-9.
45. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, (1):CD000171.
46. Roche PW, Krause V, Konstantinos A, Bastian I, Antic R, Brown L, et al. Tuberculosis notifications in Australia, 2006. Commun Dis Intell 2008, 32(1):1-11.
47. Rodger AJ, Story A, Fox Z, Hayward A. HIV prevalence and testing practices among tuberculosis cases in London: a missed opportunity for HIV diagnosis?. Thorax 2010, 65(1):63-9. 10.1136/thx.2009.122754, 19996347.
48. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. Jama 2008, 300(8):945-51. 10.1001/jama.300.8.945, 18728268.
49. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008, 12(12):1370-5.
50. World Health Organisation/Joint United Nations Programme for HIV/AIDS Strengthening health services to fight HIV/AIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. 2007, Geneva, Switzerland: WHO, World Health Organisation/Joint United Nations Programme for HIV/AIDS.
51. Centres for Diseases Control and Prevention Managing drug interactions in the treatment of HIV-related tuberculosis. 2007, [June 2009], Centres for Diseases Control and Prevention., http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/PDF/tbhiv.pdf
52. Mahendradhata Y, Ahmad RA, Lefevre P, Boelaert M, Van der Stuyft P. Barriers for introducing HIV testing among tuberculosis patients in Jogjakarta, Indonesia: a qualitative study. BMC Public Health 2008, 8:385. 10.1186/1471-2458-8-385, 2596127, 19014468.
53. Jochelson K, Mothibeli M, Leger JP. Human immunodeficiency virus and migrant labor in South Africa. Int J Health Serv 1991, 21(1):157-73. 10.2190/11UE-L88J-46HN-HR0K, 2004869.
54. Ramjee G, Gouws E. Prevalence of HIV among truck drivers visiting sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis 2002, 29(1):44-9. 10.1097/00007435-200201000-00008, 11773878.